Human CD34' cells were subfractionated into three size classes using counterflow centrifugal elutriation followed by immunoadsorption t o polystyrene cell separation devices. The three CD34+ cell fractions (Fr), Fr 25/29, Fr 33/37, and Fr RO, had mean sizes of 8.5,9.3 and 13.5 pm, respectively. The majority of cells in the large Fr R 0 CD34+ cell population expressed the committed stage antigens CD33, CD19, CD38, or HLA-DR and contained the majority of granulocyte-macrophage colony-forming units (CFU-GM), burst-forming unitserythroid (BFU-E), and CFU-mixed lineage (GEMM). In contrast, the small Fr 25/29 CD34+ cells were devoid of committed cell surface antigens and lacked colony-forming activity. When seeded t o allogeneic stroma, Fr R 0 CD34' cells produced few CFU-GM at week 5, whereas cells from the Fr 25/29 CD34+ cell population showed a 30-t o 55-fold expansion of myeloid progenitors at this same time point. Furthermore, CD34' cells from each size fraction supported ontogeny of T cells in human thymus/liver grafts in severe T HE HUMAN PLURIPOTENT hematopoietic stem cell has been postulated to respond to a variety of internal and environmental cues, giving rise to both identical copies of itself and to differentiated cells of the hematopoietic system. Several studies have focused on the isolation and characterization of these rare cells. In the mouse, pluripotent hematopoietic stem cells are Thyl'",Sca+,Lin-, and as few as 100 isolated cells were able to reconstitute both the myeloid and lymphoid compartments of lethally irradiated recipients.'.' Further separation of the Thyll",Sca+,Lin-population using the mitochondrial membrane dye rhodamine 123 subfractionates the stem cells into resting and activated subsets that differ in their ability to proliferate and reconstitute lethally irradiated primary and secondary recipient^.^.^ In humans, the CD34 antigen is expressed by both committed and primitive hematopoietic stem cells,6-' and purified CD34+ cell populations engraft lethally irradiated autologous and allogeneic Moreover, hematopoiesis has been restored in humans after high-dose chemotherapy using The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with I8 U.S.C. section 1734 solely to indicate this fact. 0 1995 by The American Society of Hematology. 0006-4971/95/8602-0020$3.00/0 512 combined immunodeficient W I D ) mice. Upon cell cycle analyses, greater than 97% of the Fr 25/29 CD34' cells were in Go/GI phase, whereas greater proportions of the two larger CD34+ cell fractions were in active cell cycle. Binding of the cytokines interleukin (lL)-la, IL-3, IL-6, stem cell factor (SCF), macrophage inhibitory protein (MIP)-la, granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage (GM)-CSF t o these CD34' cell populations was also analyzed by flow cytometry. As compared with the larger CD34' cell fractions, cells in the small Fr 25/29 CD34+ cell population possessed the highest numbers of receptors for SCF, MIPIa, and IL-la. Collectively, these results indicate that the Fr 25/29 CD34' cell is a very primitive, quiescent progenitor cell population possessing a high number of receptors for SCF and MIPla and capable of yielding both myeloid and lymphoid lineages when placed in appropriate in vitro or in vivo culture conditions.
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purified CD34+ cells." Other cell surface antigens have been used to subfractionate the CD34' population into immature and committed subsets. Specifically, antibodies against the transferrin re~eptor,'~"' CD33,14,15 CD38,16 HLA-DR,I2." CD45 7B9,20 c-kit,2',22 and combinations of lineage-specific antigens23s24 have been used to separate immature cells from committed progenitors. More recently, positive expression of both the Thy1 and CD34 antigens has been used to isolate very primitive human hematopoietic p r e~u r s o r s .~~,~~ Approximately 25% of human bone marrow CD34' cells express Thy 1, and these cells contain the vast majority of long-term bone marrow culture-initiating activity. 26 Counterflow centrifugal elutriation (CCE) has been used to separate murine pluripotent hematopoietic precursors from committed progenitor^.^"" Jones et al" used CCE to subfractionate murine bone marrow into four discrete size and density populations. The largest fraction, highly enriched for granulocyte-macrophage colony-forming units (CFU-GM), produced only short-term transient engraftment of lethally irradiated mice. The smallest fraction, which was depleted of CFU-GM and day-12 spleen colony-forming units (CFU-S), was necessary to achieve long-term reconstitution, suggesting the physical separation of committed and reconstitutive stem cells. In further studies, Yoder et a132 used CCE to separate six different subsets of murine high proliferative potential colony-forming cells (HPP-CFC). The lowest density HPP-CFC with lymphocytic morphology appeared the most primitive, requiring numerous growth factors in vitro for maximal proliferation. Using antibody selection after CCE, Orlic et al" isolated Lin-, c-kit' cells from each of the elutriated fractions. Each Lin-, c-kit+ fraction possessed pluripotent activity, yet only the small cell fraction lacked committed progenitor activity.
In this study, we used CCE to separate CD34' cells from human bone marrow into committed and more primitive populations. We demonstrate that the smallest subset, less For personal use only. on September 24, 2017. by guest www.bloodjournal.org From than 9.5 pm in diameter, is substantially devoid of lineage markers and colony-forming cells and is in the GdG, phase of the cell cycle. However, after incubation with allogeneic stroma, the cells proliferate and produce CFU-GM for at least 5 weeks. Furthermore, cells from the small fraction also repopulate fetal thymus liver grafts; producing both CD4+ and CD8+ T cells. Lastly, using biotinylated cytokines, we characterize the distribution of receptors for a variety of different hematopoietic growth factors on all size fractions of CD34+ cells. The small CD34+ fraction expresses receptors for interleukin-l (L-l), IL-3, L-6, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell factor (SCF), and macrophage inhibitory protein (MP)-la. Compared with the larger CD34+ subsets, the density of receptors for IL-la, SCF, and MIP-la on these small CD34+ cells is high, potentially priming them for response to these positive and negative regulators of hematopoiesis.
MATERIALS AND METHODS
Human bone marrow samples. Human bone marrow samples were aspirated from the posterior iliac crest of healthy volunteers using standard procedures. Informed consent was obtained following the guidelines approved by the Committee on the Use of Human Subjects at the University of Minnesota (Minneapolis, MN). Appropriate institutional approvals were obtained.
CCE. Low-density bone marrow mononuclear cells were isolated using Histopaque-l077 (Sigma Chemical CO, St Louis, MO) and density gradient centrifugation at 400g for 30 minutes at room temperature. The mononuclear cells were washed twice and resuspended in 10 mL sterile elutriation medium (Hank's buffered saline containing 0.5% human serum albumin [HSA] and 0.3 mmol/L EDTA, pH 7.2). The cells were injected via a sampling site coupler into the inlet stream of a Beckman J6M/E centrifuge (Spenco Division, Beckman Instruments, Palo Alto, CA) equipped with a JE-5.0 rotor and standard chamber. One peristaltic pump (Masterflex; Cole Palmer Instruments, Chicago, K) provided continuous flow of elutriation media. Cells were delivered at a total flow rate of 15 mL/min (Fr 15), at a rotor speed of 3,000 rpm and a temperature of 25°C. After 100 mL of eluate was collected, the flow rate was increased to 25 mL/min (Fr 25). With the rotor speed held constant, the flow rates were sequentially increased to 29 mL/min (Fr 29), 33 min (Fr 33), and 37 mL/min (Fr 37), collecting 200 mL with each increment. The cells that remained in the chamber were captured by turning the rotor off (Fr RO) and flushing the chamber with 100 mL of elutriation media. The cell fractions were washed and centrifuged at 300g for 10 minutes. Fractions 25 and 29 (Fr 25/29) and fractions 33 and 37 (Fr 33/37) were pooled for these experiments. Viability was determined by trypan blue exclusion, and cell numbers were determined by either hemacytometer counts or by a ZBT Coulter Counter (Coulter Electronics, Hialeah, FL).
Isolation of CD34+ cells. Cells obtained after the elutriation procedure were collected by centrifugation, washed with elutriation medium, and resuspended in Dulbecco's phosphate-buffered saline Ca/Mg-free containing 1 mmol/L EDTA (DPBSE), and 0.5% Gamimune (Cutter Biological, Miles, Inc, Berkeley, CA) for CD34 isolation using the method of Lebkowski et al. 33 The cells were incubated for 20 minutes at room temperature and loaded into AIS MicroCELLectors SBA (Applied Immune Sciences, Inc, Santa Clara, CA), which contain covalently immobilized soybean agglutinin (SBA). Up to 2 X lo7 cells were loaded per flask and incubated for 1 hour at room temperature. The nonadherent (SBA-) cells were removed and subsequently loaded into AIS MicroCELLectors CD34. Up to 2 x lo7 cells were loaded onto these devices, which contain the covalently immobilized anti-CD34 monoclonal antibody, ICH3.' After incubation for l hour at room temperature, the nonadherent (CD343 cells were removed, and the adherent (CD347 cells were collected after physical agitation in DPBSE containing 10% fetal bovine serum (FBS) or 0.5% HSA. The released cells were withdrawn, the devices were rinsed with DPBSE, and the cells were collected after centrifugation in tubes that had been precoated with 5% HSA.
Light microscopy of CD34' cells. Cytospin slides were separately prepared for each of the three elutriated CD34+ cell fractions. The cells were stained with Wright's stain and visualized by light microscopy. Photographs were taken at 450X magnification.
Light scatter and cell size determination. Methylcellulose cultures for progenitors. Cells were cultured in 0.9% methylcellulose containing phytohemagglutinin-stimulated leukocyte conditioned medium and erythropoietin (Stem Cell Technologies, Vancouver, BC). Cultures were seeded in triplicate, 1 mL culture in 35 mm dishes, and maintained in a humidified atmosphere at 37°C in 5% CO,. The plates were scored at 14 to 18 days using an inverted microscope for CFU-GM, burst-forming unit-erythroid (BFU-E), and mixed lineage (CFU-GEMM) colonies.
Long-term bone marrow culture. Normal allogeneic stromal layers were established from bone marrow mononuclear cells in T-25 flasks (Corning Gear Works, Corning, NY) in long-term bone marrow culture medium, McCoy's 5A medium supplemented with 12.5% FBS (HyClone Labs, Logan, UT), 12.5% horse serum (HyClone Labs), 2 mmoVL L-glutamine, 0.7% sodium bicarbonate, 1% (vol/vol) minimum essential medium (MEM) nonessential amino acids (Life Technologies, Grand Island, NY), 1% (voUvol) MEM vitamin solution (Life Technologies), 1% (vol/vol) sodium pyruvate (Life Technologies), 100 U/mL penicillin, 100 &mL streptomycin, and 10" mol/ L hydrocortisone (A-Hydrocort; Abbott Laboratories, Chicago, K). Stromal layers were cultured 21 to 28 days, d a t e d at 1,500 cGy, and used to support long-term bone marrow culture using a modification of the method of Gartner and Kaplan." Immediately after isolation, 1 X lo4 CD34+ cells from each of the size fractions were seeded onto the stromal layers to initiate the cultures. Cultures were maintained in a humidified atmosphere at 37°C in 5% CO,. At weeks 2 and 5 of culture, the nonadherent layer was removed and the adherent layer was collected after trypsinization. Cells from the nonadherent and adherent layers were enumerated, and 1 X lo4 cells from each fraction were cultured in methylcellulose progenitor culture (see above). Colonies were quantitated 14 to 18 days after culture.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Cell cycle analysis. For cell cycle analysis, 0.5 X 10' to 1.0 x IO6 CD34' cells and its subsets were mixed and incubated in 300 to 500 mL of DNA fragmentation buffer (0.5 m o m EDTA, Triton X, 1 mg/mL propidium iodide, 1% RNase A in DPBS) for 10 minutes at 4°C in the dark. Chick erythrocytes were prepared as a control. DNA content as measured by fluorescence intensity was determined using a FACScan flow cytometer (Becton Dickinson) and analyzed using the manufacturer's program Cell Fit.
Characterization of growth factor receptor distribution. CD34' cell subsets were assayed for the presence of receptors for SCF (ckit ligand), GM-CSF, G-CSF, IL-l, L-3, E-6, and MIP-la. For such analyses, 1 X 10' cells were washed twice in HEPES buffered saline (150 mmoVL NaCI, 25 mmoVL HEPES pH 7.4) and incubated with 100 ng of biotinylated growth factor (R&D Systems, Minneapolis, MN) for 60 minutes on ice. After incubation, the cells were washed twice in 2 mL of RDFI wash buffer (R&D Systems) and subsequently incubated with 100 ng avidin-carboxyfluroescein (R&D Systems) for 30 minutes on ice in the dark. The cells were again washed with 2 mL of RDFI buffer and resuspended in 300 pL of HEPES buffered saline. Stained cells were analyzed for fluorescence intensity on either an EPICS Profile I1 or Epics 752 flow cytometer (Coulter Electronics). The percent fluorescence positivity and mean channel fluorescence were measured. Positive samples were stained with avidin-carboxyfluorescence alone. Specificity of binding of the biotinylated cytokine was confirmed by inhibition of binding in the presence of a 100-molar excess of unlabeled growth factor.
Establishment of CD34+ cell subsets in thymush'iver grajis in SCID-Hu mice. SCID-Hu mice were established using modified procedures of Namikawa et al, 35 McCune et al? 6 and Rowley et CB 17 SCID mice (Taconic, Germantown, NY) were received at 8 weeks of age and housed in standard microisolator cages. All procedures were approved by the Applied Immune Sciences Institutional Animal Care and Use Committee. Five days before surgery, the animals were given Ciprofloxacin (Cipro; Miles, Inc) in their drinking water, which was continued until 10 days postsurgery. Human fetal thymus and liver from 18-to 22-week gestation fetuses were obtained after curettages after informed consent. Pieces of both fetal thymus and liver were placed in direct contact under the kidney capsules of the SCID mice. Pentobarbital anesthesia was used for all surgical procedures. At 10 weeks postimplantation of the thymudliver graft, a second surgical procedure was performed to seed 10, OOO to 50,000 of the CD34' cell subsets. For this procedure, the CD34' cells were directly injected into the thymusfliver graft in a volume of 1 to 2 pL. For these analyses, the thymudiver graft and cells from the donor of the CD34' cells were HLA-typed for various class I markers. The CD34' cells were seeded into thymudiver grafts with at least one disparate class I marker, so that the seeded cells could be tracked after implantation. The following antibodies were used for HLA typing: HLA-A2, clone BB7.2; HLA-A3, clone GAPA3; HLA-A11/A24, clone A11.1M; HLA-BS, clone 4D12; HLA-B7, clone BB7.2 (American Type Culture Collection, Rockville, MD). Fluorescent analysis of stained cells was performed as described above. Ten weeks after CD34' cell seeding, the animals were killed, and the graft tissue was removed. The tissue was dispersed, and the mononuclear cells were isolated using Histopaque 1077 (Sigma, St Louis, MO). The origin of the cells in the graft was determined by two-color fluorescence analysis using monoclonal antibodies specific for the human CD45 antigen (clone 2D1; Becton Dickinson) and the appropriate HLA class I marker. The lineage of the cells was further determined using appropriate major histocompatibility complex (MHC) class I and lineage-specific monoclonal antibodies.
RESULTS
For these studies, CCE was used to subfractionate adult bone marrow CD34' cells. To start the process, bone marrow mononuclear cells (BMMC) were separated by CCE into three fractions, Fr 25/29, Fr 33/37, and Fr RO, based on the flow rate of the elutriation buffer and rotor speed. Fr 25/29, Fr 33/37, and Fr R 0 contained, on average, 33.9%, 25.6%, and 31.9% of the starting BMMC population, respectively (Table I) . CD34' cells were separately isolated from each of the three elutriation fractions. Of the CD34' cells that were isolated by these procedures, IO%, 35%, and 60% were recovered in the Fr 25/29, Fr 33/37, and Fr R 0 fractions, respectively. A mean 0.06%, 0.2%, and 0.4% of the BMMC were found in the final CD34+ cell populations from Fr 25/ 29, Fr 33/37, and Fr R 0 samples, respectively ( Table 1) .
CD34+ cells from each of the elutriation fractions were visualized by light microscopy (Fig l) . Cells in Fr 25/29, Fr 33/37, and Fr R 0 CD34' were progressively larger in size with distinct morphologies. The Fr 25/29 CD34' cells were lymphocyte-like with relatively scant cytoplasm, large homogeneous nuclei, and rare nucleoli. The Fr 33/37 CD34' cells were lymphoblast-like with more cytoplasm, large nuclei, and one to three nucleoli. CD34+ cells of the Fr R 0 were myeloblast-like with large amounts of cytoplasm-containing granules, large granular nuclei, and multiple nucleoli.
The relative sizes of the three CD34' cell fractions were confirmed by light scatter analysis. Figure 2 shows the forward versus side scatter of the input BMMC and the three CD34+ cell fractions. All of the cell samples showed relatively low side scatter, indicating low levels of granularity in all of the populations. The Fr 25/29 (Fig 2B) , Fr 33/37 (Fig 2C) , and Fr R 0 (Fig 2D) CD34' cell fractions show progressively increasing forward scatter, confirming their increasing cell size. The mean forward scatter was determined for each CD34+ cell fraction and plotted on a standard forward scatter curve generated using beads of known size. Using such analysis, the average sizes of the Fr 25/29, Fr 33/37, and Fr R 0 CD34' cells were 8.5 ? 1.5, 9.3 t 1.4, and 13.5 ? 2.0 pm, respectively.
The BMMC-elutriated fractions and the purified CD34' cells were immunophenotyped for a variety of antigens (Table l). The input BMMC fraction had, on average, 3.3% CD34' cells. The percentage of CD34' cells remained relatively constant in the elutriated fraction, with 2.0%, 7.6%, and 5. To test the short-term hematopoietic function of the various cell fractions, CFU-GM, BFU-E, and CFU-GEMM progenitor colonies were enumerated. The results of seven such experiments are shown in Table 2 . When the unseparated BMMC were fractionated by elutriation, the bulk of the progenitor activity tracked into the larger Fr R 0 and intermediate Fr 33/31 populations. In contrast, very few progenitors were found in the small cell Fr 25/29 population. Similar results were observed when CD34+ cells were isolated from the elutriated fractions.
All three CD34+ cell fractions showed substantial enrichment of colony activity over their elutriated unpurified counterparts, with 10-to 60-fold enrich- and plated in methylcellulose culture, and CFU-GM were enumerated. Figure 3A and B shows the number of colonies observed at weeks 0, 2, and 5 in these long-term bone marrow cultures in two experiments. Figure 4 shows the foldincrease in CFU-GM at 5 weeks of stromal culture of each of the CD34' cell fractions. In all experiments performed to date, the vast majority of CFU-GM activity was observed in the adherent layers of the stromal based cultures (data not shown). In both experiments shown in Fig 3 and in all cultures tested, the cultures seeded with the Fr R 0 CD34' cells contained the greatest number of initial CFU-GM. Despite this large number of progenitors, the number of CFU-GM increased by a maximum of 25% or decreased in number by week 2 of culture. In all Fr R 0 cultures, the number of CFU-GM decreased by 60% to 80% by week 5 of culture. CD34' cells from the Fr 33/37-elutriated fraction produced moderate increases in CFU-GM number after long-term stromal culture ( Figs 3A and B and 4) . Peak CFU-GM production was observed at 2 weeks, with approximately fourfold increases in colonies at this time point. After further culture to 5 weeks, colony production from the Fr 33/37 CD34' cells decreased to 80% to 300% of that at the initial starting point. In contrast, the Fr 25/29 CD34" cells increased in CFU-GM number at both 2 weeks and 5 weeks of stromal culture ( Figs  3A and B and 4) . The CFU-GM from the Fr 25/29 CD34' cells increased 4-to 40-fold at 2 weeks, and 25-to 55-fold at 5 weeks of culture (Figs 3 and 4) .
The cell cycle status of the three CD34' cell fractions was analyzed. Using propidium iodide staining (see Materials and Methods), cells containing normal 2N and greater amounts of DNA were quantitated. Figure 5 shows the fluorescence traces of the various CD34' populations, and the percentage of cells in the different phases of the cell cycle. In these analyses, the purity of cells in each of the three CD34' cell fractions was greater than 85%. In unfractionated bone marrow, approximately 90% of the cells were in the G&, stage, with 10% in either S phase or active division. To further analyze the hematopoietic activity of the three CD34' cell fractions, 25,000 to 50,000 of these cells from adult bone marrow were injected into human fetal thymus/ liver grafts that had previously been established in CB 17 SCID mice. For these experiments the purity of the seeded Fr 25/29, Fr 33/37, and Fr R 0 CD34' cells exceeded 50%, 94%, and 92%, with less than 25%, 3%, and 1 % contaminating CD34' T cells, respectively. In these studies, the thymus/ liver graft and the donor of the CD34' cells had been HLA class l-typed. To track the donor CD34' cells after injection, only graft-donor CD34' cell pairs with at least one identified HLA mismatch were used. Ten weeks after seeding of the thymusfliver grafts, the grafts were harvested and phenotyped for the presence of human CD45' cells of the donor CD34' cell HLA type. Table 3 shows the results from three independent experiments. When no donor CD34' cells were administered, none of the grafts showed evidence of donortype human cells. In contrast, 23%, 30%, and 40% of the thymusfliver grafts seeded with Fr 25/29, Fr 33/37, and Fr R 0 CD34' cells, respectively, showed evidence of donorderived cells IO weeks after seeding. Approximately 35% to 48% of the cells were of donor origin. These results are approximately equivalent to our previous results with unfractionated CD34' cells, where approximately 40% of the seeded grafts possessed donor-derived cells (data not shown). The cells from the SCID-Hu grafts were further phenotyped. The CD3 T-cell marker was present on 79% to 99% of the donor-derived cells (Fig 6) , with 35% to 83% of the cells being CD4' and 55% to 78% being CD8'. CD4'CDS' cells were also observed. The results indicate that CD34' cells from the three CD34' populations not only produce myeloid cells but yield cells of the T-cell lineage when provided the appropriate microenvironment.
To further characterize the three CD34' cell populations, surface receptors for a variety of hematopoietic growth factors were analyzed using flow cytometry. In these studies, the cells were incubated with biotinylated cytokines and counterstained with fluorescein isothiocyanate (F1TC)-conjugated avidin. For these analyses, only the CD34' cells were analyzed using two-color flow cytometry. The cytokine fluorescence profile and the mean fluorescence were determined by flow cytometry. Figure 7 shows representative fluorescence histograms from one experiment where the Fr 25/29, Fr 33/37, and Fr R 0 CD34' cells were tested for receptors for seven different growth factors: IL-la, IL-3, IL-6, G-CSF, GM-CSF, SCF, and MIP-la. In most cases, fluorescence with the bound growth factor appeared as a single, sometimes broad, peak. As a control, minimal to no binding was observed in the CD34-fractions (data not shown). The fluorescent growth factor binding could be quenched in the presence of a 100-fold excess of the nonbiotinylated growth factor (Fig g) , indicating the specificity of binding.
The level of growth factor binding was examined for each of the three CD34' cell fractions. Only G-CSF showed less than 25% increases in fluorescence over negative controls in all three CD34' cell fractions. With the other six growth factors, there was a consistent trend in which the smaller CD34' cell fractions possessed higher mean fluorescence levels and consequent growth factor binding. In greater than 80% of the determinations for each growth factor, the fluorescence intensity of cytokine binding in the Fr 25/29 CD34' cells was greater than that observed for the Fr R 0 CD34' cells. When statistically compared, P values of less than . l were observed for IL-la ( P = .027), MIP-la ( P = .006), and SCF ( P = .081), suggesting significantly higher fluorescence binding of these growth factors to the smaller Fr 25/29 CD34' cells.
DISCUSSION
In this report, we isolate and characterize subpopulations of human CD34' cells that differ in size and .density. The individual size fractions, having mean diameters of 8.5, 9.3 and 13.5 pm, have distinct phenotypic profiles and prolifera- For In contrast, the small Fr 25/29 CD34' cells appear to be a quiescent primitive cell population that is almost devoid of the tested surface antigens. In fact, all differentiation antigens detected in the population could be attributed to contaminating T cells in some of the preparations. The actual CD34' cells did not coexpress the CD3, CD19, CD33, CD38, or HLA-DR antigens. The Fr 25/29 CD34' cells do not proliferate in methylcellulose culture yet produce greater than 100-fold increases in CFU-GM after long-term culture on allogeneic stroma. It is the only one of the three CD34' cell fractions that continues to proliferate and increase CFU-GM production after 5 weeks in long-term bone marrow culture. Moreover, the Fr 25/29 CD34' cells appear especially sensitive to culture conditions; these cells do not proliferate in normal progenitor colony assays, and our attempt to grow these cells in any stroma-free system using single growth factors or combinations of the growth factors IL-3, IL-l, IL-6, SCF, G-CSF, GM-CSF, erythropoietin, basic fibroblast growth factor, and IL-l1 uniformly did not reproducibly support growth. To date, we have only observed extensive in vitro proliferation of these cells in the adherent layers of stromal cultures supplemented with 100 ng/mL of SCF. Very few CFU-GM were observed in the nonadherent layers in these same cultures at up to 5 weeks. These findings are consistent with those of Rowley et al,"7 who showed that primitive 4-hydroperoxycyclophosphamidetreated CD34TD38-cells could only be maximally stimulated when both growth factors and marrow stroma were used.
CD34' cells from each of the three size fractions reconstituted fetal thymusfliver grafts implanted in SCID-Hu mice. At I O weeks after implantation, CD3' T cells of donor origin were observed in 30% to 40% of the grafts. In these studies, the donor T cells observed in the grafts most likely derived from the seeded CD34' cells. In all cases, the seeded CD34' cells were at least 50% pure, and the Fr 33/37 and Fr R 0 CD34' cells were greater than 92% pure. In the Fr 33/37 and Fr R 0 populations, less than 3% of the seeded cells were contaminating T cells. Moreover, in all cases examined, double-positive donor CD4'CDS' T cells could also be observed, suggesting the development and maturation of T cells from an earlier precursor. The data confirm that cells from adult bone marrow can be established and expanded 10-to 100-fold in such mouse models. The results further demonstrate that the Fr 25/29 CD34' cells have multipotential activity leading to both the production of myeloid cells in vitro and lymphoid cells in SCID-HU mice. Notably, CD34' cells from the large R 0 fraction were also found to produce T cells in this mouse model at the same frequency and level as the small Fr 25/29 CD34' cells. These data suggest the possible presence of multipotent cells in all size fractions, and that CD34' cells, which do not express T-cell lineage markers or which express certain myeloid lineage markers, can produce T lymphocytes after culture on adherent thymic stromal cells. This latter conclusion is consistent with recent results using thymic organ cultures.3*~39
Other investigators have used CCE as an initial step in the isolation of primitive human stem Cells isolated using this method have also been shown to engraft xenogeneic sheep.'" In these isolation procedures, fractions at flow rates of 12 to 14 mUmin are collected at a rotor speed of 1,950 rpm before CD34' cell selection and subsequent DR' cell depletion. Cells collected using these conditions range from 9.5 to 1 I pm and most closely correspond in size to those cells found in the Fr 33/37 population. This correspondence is further suggested by the frequency of day-14 CFU-GM or BFU-E progenitors in Fr 12/14 CD34' cells and Fr 33/37 CD34' cells, which was higher than those presented here for the fraction 25/29 CD34' cells. Therefore, the small Fr 25/29 cells represent a smaller sized population of primitive stem cells separated from more committed progenitors that have been discarded in other isolation procedures. Importantly, these cells can be isolated without extensive lineage-specific cell depletion.
Receptors for IL-l, IL-3, IL-6, G-CSF, GM-CSF, SCF, and MIP-la were examined in all three CD34' cell fractions by examining direct cytokine binding to cells. Although the methods used here cannot be used to determine the actual number of receptors in such cells, it can be used to characterize the relative numbers of receptors on cells from different populations. The specificity of these methods was confirmed by a number of control experiments. The biologic activity of the biotinylated growth factor was confirmed in growth assays using growth factor-dependent lines. The biotinylated cytokines were also compared with native cytokines in Scatchard analyses for their ability to displace "'I-labeled cytokines on reference cell lines known to express specific receptors. Lastly, the specificity of the reactivity of the biotinylated cytokines was further confirmed by the inability of nonmatching cytokines to block the binding of the biotinylated reagents.
In these studies, binding sites were found for IL-I, IL-3, IL-6, G-CSF, GM-CSF, SCF, and MIP-la on each of the three CD34' cell populations. Significant cytokine binding levels were not observed on the CD34-cells. After analysis of the mean channel fluorescence of growth factor binding to the CD34' cells, trends were observed suggesting that the density of receptors for all of these growth factors on the Fr 25/29 CD34' cells was much higher than on the large CD34' cell fraction. Statistical significance was achieved for SCF, IL-la, and MIP-la. This increased density of receptors on the small cell fraction becomes especially significant when one considers the relative sizes of the cells and the mean fluorescence per square micrometer of cell surface area. This type of analysis of receptor binding has been previously described by Shabtai et al: ' The proportion of these growth factor binding sites that are functional is unknown. Moreover, the exact function for the high density of receptors is also unknown. These receptors might help sensitize these cells to respond to these agonists, and the fractional occupancy of these receptors may help modulate their reactivity in the marrow microenvironment.
Receptors for SCF have been previously characterized on hematopoietic progenitors using specific monoclonal antibodies to c-kit. In the mouse, differing levels of c-kit receptors have been demonstrated on stem cells. Ikuta and Weissman4' showed that 70% to 80% of Thy1 ',Sca',Lin-cells express c-kit, and when this population was fractionated into c-kit+ and c-kit-cells, only the c-kit' cells led to the production of donor-derived cells in irradiated mice. Katayama et For personal use only. on September 24, 2017. by guest www.bloodjournal.org From alM suggested that the most primitive stem cells as found in 5-fluorouracil-treated animals were c-kit", which eventually increased in intensity after cycling. In contrast, Oriic et a130 found the primitive repopulating stem cells in untreated mice to be c-kit bright and rhodamine dull. Similar studies have been reported for the human stem cell population. Briddell et al" showed that only the c-kit+ fraction of CD34+, HLA-DR-cells generated progenitors after 10 weeks in culture. Moreover, using stromal cultures, Gunji et a12' suggested that the majority of long-term bone marrow culture-initiating cells were c-kit'", whereas colony-forming cells were c-kithi. Again, c-kit-cells showed little hematopoietic activity. These results are in agreement with our results that the primitive CD34+ cells do express receptors for SCF. Any difference in the perceived levels of receptors in these studies may reflect the different assays used to detect receptors. In our studies, direct growth factor binding is measured, whereas in these other studies, specific antibodies are used to indirectly detect receptors. In such assays, measurement of alternative receptors may be missed.
The primitive Fr 25/29 CD34' cells were found to have a high density of binding sites for both L -3 and MIP-la. This finding is complementary to the recent results of Verfaillie et al?' who showed that MIP-la together with IL-3 could lead to the maintenance of long-term bone marrow culture-initiating cells in noncontact stromal cultures. Results indicated that these factors exerted their effects only by direct interaction with the CD34+, HLA-DR-cells.
These studies with human stem cells are in agreement with findings using CCE to study murine hematopoietic progenitor~.~"~' As in the murine system, progenitors capable of long-term hematopoietic activity can be found in all fractions. However, the small Fr 25/29 CD34+ cell fraction is devoid of progenitor activity, yet is most enriched in cells that initiate long-term bone marrow cultures. Although direct evidence for the long-term repopulating activity of this cell in humans is not available, several clinical observations support this hypothesis. In clinical studies where CCE has been used for T-cell depletion in allogeneic bone marrow transplantation, cells of this size range are eliminated from the final graft due to the high concentration of T lymphocytes in these fractions. Patients transplanted with such manipulated grafts, although showing early engraftment with reduced graft-versus-host disease, have a higher rate of late graft failure and mixed chimerism as compared with patients receiving unseparated bone marrow?6 Clinical studies are now underway to evaluate whether the purification and infusion of these CD34' cells from the normally discarded fractions will improve engraftment after CCE-manipulated grafts.
The Fr 25/29 CD34' cells could be a useful starting population to study the interaction of soluble factors and elements of the stromal microenvironment that act to control proliferation and differentiation of hematopoietic stem cells. Most importantly, successful expansion and manipulation of these cells will lead to broad clinical applications in transfusion, transplantation, and gene therapy.
